Clinical trials: Trypanosomiasis, African
Human African Trypanosomiasis
Assessment of Recombinant HAT-RDT Specificity
Human African trypanosomiasis HAT, or sleeping sickness, is a tropical disease caused mainly by the parasite Trypanosoma brucei gambiense (gHAT).
- Trial name
- NCT05637632
- Where
- Democratic Republic of the Congo
- Volunteers
- 1,504 people, healthy volunteers welcome
- Sponsor
- Institute of Tropical Medicine, Belgium
Trypanosomiasis, African
Multiple Dose Study to Evaluate Security, Tolerance and Pharmacokinetic of Fexinidazole (Drug Candidate for Human African Trypanosomiasis) Administered With a Loading Dose and With Food
This trial will study the tolerability and pharmacokinetic of fexinidazole using two different dosage regimen of repeated administrations.
- Trial name
- NCT01483170
- Testing
- Tablets Fexinidazole
- Where
- France
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Drugs for Neglected Diseases
Trypanosomiasis, Trypanosomiasis, African
Human African Trypanosomiasis: First in Man Clinical Trial of a New Medicinal Product, the SCYX-7158
This study is aimed at assessing the tolerability and pharmacokinetic parameters of SCYX-7158 in healthy volunteers. In animal models of both acute and chronic experimental Trypanosomiasis infections, SCYX-7158 shows highly…
- Conditions
- Trypanosomiasis, Trypanosomiasis, African, Protozoan Infections, Parasitic Diseases
- Trial name
- NCT01533961
- Testing
- SCYX-7158
- Where
- 2 sites in France
- Volunteers
- 136 people, healthy volunteers welcome
- Sponsor
- Drugs for Neglected Diseases
Trypanosomiases, African
ADME Study of Acoziborole in Healthy Subjects
This is a single centre, open-label, single group, non-randomised, single oral dose study in healthy male subjects designed to assess the mass balance recovery, PK, metabolite profile and metabolite identification, and…
- Trial name
- NCT04270981
- Testing
- [14C]-acoziborole capsule, 240 mg containing NMT 9.25 kBq (250 nCi) 14C
- Where
- United Kingdom
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- Drugs for Neglected Diseases
Human African Trypanosomiasis
Prospective Evaluation of an RDT to Screen for Gambiense HAT and Diagnose P. Falciparum Malaria
A prototype rapid diagnostic test (RDT) to simultaneously screen for gambiense human African trypanosomiasis (HAT) and diagnose P. falciparum malaria (the "HAT/malaria combo") has recently been developed.
- Trial name
- NCT03394976
- Testing
- No intervention
- Volunteers
- healthy volunteers welcome
- Sponsor
- Foundation for Innovative New Diagnostics, Switzerland
Human African Trypanosomiasis
Human African Trypanosomiasis: First in Man Clinical Trial of a New Medicinal Product, the Fexinidazole
This study is aimed at assessing the tolerability and pharmacokinetic parameters of the fexinidazole in healthy volunteers. In animal models of both acute and chronic experimental Trypanosomiasis infections, fexinidazole shows…
- Trial name
- NCT00982904
- Where
- France
- Volunteers
- 108 people, healthy volunteers welcome
- Sponsor
- Drugs for Neglected Diseases
Trypanosomiasis, African
DDI Study of Single Oral Dose of Acoziborole With Sequential Co-administration of Midazolam and Dextromethorphan
To assess Drug drug interactions between Acoziborole and Dextromethorphan and Midazolam in healthy male volunteers.
- Trial name
- OXA-07 (NCT05947604)
- Testing
- Acoziborole, Midazolam, Dextromethorphan
- Where
- Malaysia
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Drugs for Neglected Diseases
PK in Healthy Volunteers
Fexinidazole (1200mg) Bioavailability Under Different Food Intake Conditions
The present study is designed to assess the impact of concomitant food intake on the relative bioavailability of a single oral fexinidazole tablet administration.
- Trial name
- NCT01340157
- Testing
- Fexinidazole
- Where
- France
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Drugs for Neglected Diseases
Human African Trypanosomiasis, Sleeping Sickness
Diagnostic Tools for Human African Trypanosomiasis Elimination and Clinical Trials: WP3 Post Elimination Monitoring
This study determines the feasibility, diagnostic performance and cost for monitoring of eliminated human African trypanosomiasis (HAT) foci using diagnostic algorithms of serological and molecular high throughput tests with and…
- Conditions
- Human African Trypanosomiasis, Sleeping Sickness, Trypanosoma Brucei Gambiense; Infection, West African Sleeping Sickness
- Trial name
- DiTECT-HAT-WP3 (NCT04099628)
- Testing
- Rapid diagnostic test (RDT); Serological and molecular tests on DBS
- Where
- 3 sites in Burkina Faso, Côte d’Ivoire and 1 more
- Volunteers
- 13,747 people, healthy volunteers welcome
- Sponsor
- Institut de Recherche pour le Developpement
Trypanosomiasis, African
Bioequivalence Study - Reference Clinical Fexinidazole Tablet Versus Proposed Market Formulation
Phase 1 bioequivalence (BE) study. This study is for regulatory purpose to determine BE of the tablet formulation used in the clinical trials and the final marketed tablet formulation under fed condition.
- Trial name
- NCT02571062
- Testing
- Fexinidazole
- Where
- France
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Drugs for Neglected Diseases
Human African Trypanosomiasis, Sleeping Sickness
Prospective Evaluation of the Specificity of Serological Tests for Human African Trypanosomiasis
This study evaluates and compares the diagnostic specificity of 5 serological field tests for screening of the population at risk for human African trypanosomiasis due to Trypanosoma brucei gambiense.
- Conditions
- Human African Trypanosomiasis, Sleeping Sickness, Trypanosoma Brucei Gambiense; Infection, West African Sleeping Sickness
- Trial name
- SpeSerTryp (NCT05466630)
- Testing
- Serological field test for HAT, malaria rapid test, Immunologic laboratory tests
- Where
- 2 sites in Côte d’Ivoire, Guinea
- Volunteers
- 1,095 people, healthy volunteers welcome
- Sponsor
- Institut de Recherche pour le Developpement